Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 0.1% – Still a Buy?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) rose 0.1% on Wednesday . The stock traded as high as $11.99 and last traded at $11.95. Approximately 236,477 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 1,536,873 shares. The stock had previously closed at $11.94.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Monday. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Down 0.2 %

The business has a 50-day moving average price of $29.36 and a two-hundred day moving average price of $25.32. The company has a market cap of $22.28 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($23.00) earnings per share for the quarter, beating the consensus estimate of ($203.00) by $180.00. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.